Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Boniva is a prescription bisphosphonate containing ibandronate sodium. Oral ibandronate is approved for treatment and prevention of osteoporosis in postmenopausal women. It increases bone mineral density and reduces vertebral fracture incidence. The commonly used oral regimen consists of one 150 mg tablet taken once monthly on the same date each month.
read more about boniva ...Ibandronate binds to mineralized bone and inhibits osteoclast activity. Osteoclasts are cells that break down bone tissue during normal bone remodeling. Reducing osteoclast-mediated bone resorption slows bone loss and shifts remodeling toward greater preservation of bone mass in postmenopausal women with osteoporosis.
Boniva tablets are used for treatment and prevention of osteoporosis in postmenopausal women. Continued bisphosphonate therapy is reassessed periodically. Patients at lower fracture risk are considered for discontinuation after three to five years of use, followed by periodic reassessment of fracture risk.
The 150 mg tablet is taken once monthly after getting up for the day, at least 60 minutes before the first food, drink other than plain water, medicine, or supplement. The tablet is swallowed whole with 6 to 8 ounces of plain water. Patients remain sitting or standing for at least 60 minutes after the dose.
Oral ibandronate can irritate the esophagus and upper digestive tract. Other concerns include low blood calcium, severe bone or muscle pain, osteonecrosis of the jaw, and atypical femur fractures. It is contraindicated with certain esophageal disorders, inability to sit or stand upright for 60 minutes, hypocalcemia, or serious hypersensitivity.
Yes. Boniva contains ibandronate, a bisphosphonate that reduces osteoclast-mediated bone resorption.
The commonly used oral regimen is one 150 mg tablet once monthly on the same date each month.
Remaining upright for at least 60 minutes lowers the risk of irritation or injury to the esophagus.
No. The tablet is taken with plain water only, at least 60 minutes before other drinks, food, medicines, or supplements.
Bisphosphonate. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470248/. Date Accessed September 16, 2026.
BONIVA (ibandronate sodium) tablet, film coated. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6d7711f-541b-47d1-b937-2c6a021eb6c3. Date Accessed September 16, 2026.
IBANDRONATE SODIUM tablet. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f94d9c49-245a-8081-42c4-785113fce498. Date Accessed September 16, 2026.
Ibandronate. MedlinePlus. https://medlineplus.gov/druginfo/meds/a605035.html. Date Accessed September 16, 2026.
Supplement Approval - Boniva (ibandronate sodium) Tablets. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/021858Orig1s019ltr.pdf. Date Accessed September 16, 2026.